Christa K Goodell

Dr. Christa K Goodell

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
Nagwa KhaledNagwa Khaled
Nagwa Khaled
CGCarissa Elizabeth Gaghan
Carissa Elizabeth Gaghan
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
CGChrista K Goodell
Christa K Goodell
WSWilliam Alan Stanley
William Alan Stanley
IGIsabel M. Gimeno
Isabel M. Gimeno
Very virulent plus Marek’s disease virus (vv+MDV) induces severe immunosuppression in commercial chickens. In this study, we evaluated how three Gallid alphaherpesvirus 2 (GaHV-2) vaccines (CVI-988, rMd5-BAC∆Meq, and CVI-LTR) protected against two negative outcomes of vv+MDV infection: (1) reduced viability and frequency of immune cells in the spleen and (2) decreased efficacy of the CEO (chicken embryo origin) vaccine against infectious laryngotracheitis challenge. At 25 days post-infection with vv+MDV 686, all vaccines are protected against the reduced viability of splenocytes. However, there were differences in the frequency of splenic immunophenotypes among groups. Compared to the uninfected control, the frequency of B cells was reduced in the CVI-988/686 group but not in the rMd5-BAC∆Meq/686 and CVI-LTR/686 groups. T cell subset frequencies showed no difference between the negative controls and CVI-988/686; however, there was a reduction in activated CD4+ T cells in the rMd5-BAC∆Meq/686 group and in activated CD4+, activated CD8+, and γδ+ T cells in the CVI-LTR/686 group. We also demonstrated that the three vaccines protected against MDV-induced tumors, but only rMd5-BAC∆Meq and CVI-LTR protected against the negative impact of vv+MDV 648A strain on CEO vaccine efficacy. Our findings demonstrate important differences in the biology and/or mechanisms of protection of these vaccines.

29 May 2019 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
SMSamantha Mehling
Samantha Mehling
AHAlexandra Henao-Diaz
Alexandra Henao-Diaz
JMJeremy Maurer
Jeremy Maurer
EKEd Kluber
Ed Kluber
RSRachel Stika
Rachel Stika
DBDavid Baum
David Baum
Modern commercial pig production is a complex process that requires successful producers to understand and resolve factors associated with perturbations in production. One important perturbation is inventory loss due to mortality. In this study, data on 60 lots of approximately 2000 weaned pigs (n = 115,213) from one commercial production system were collected through the wean-to-finish (WTF) cycle with the objective of establishing patterns of mortality, estimating differences in profit/loss among patterns of mortality, and identifying production practices associated with mortality patterns. Information provided by the production system included the number of pigs in each lot at the time of placement (beginning inventory), weaning weight, barn dimensions, number of dead pigs (NDP) daily, capacity placed (proportion pigs actually placed versus what had been planned to be placed) and average weight sold. Analysis of NDP revealed three mortality patterns (clusters I, II, III) composed of 6, 40, and 14 lots, respectively, that differed in the temporal onset and/or level of mortality. Average daily gain (ADG) and feed conversion ratio (FCR) were calculated by growth phase for each cluster. An economic model showed profit differences among clusters due to poor biological performance by clusters I and III in the late finishing phase. Cluster II (n = 40) had fewer dead pigs and the highest profit compared to clusters I (n = 6) and III (n = 14). Area per pig (stocking density) was the only factor associated with the differences in mortality patterns. Routine monitoring and the analysis of mortality patterns for associations with production and management factors can help swine producers improve biological performance and improve profit.

14 July 2026 in Vaccine
Verified
Journal Article
Open access
Nagwa KhaledNagwa Khaled
Nagwa Khaled
CGCarissa Elizabeth Gaghan
Carissa Elizabeth Gaghan
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
CGChrista K Goodell
Christa K Goodell
WSWilliam Alan Stanley
William Alan Stanley
IGIsabel M. Gimeno
Isabel M. Gimeno
Very virulent plus (vv+) Marek's disease virus (MDV) strains are highly immunosuppressive and cause marked alterations in splenic immune cell populations in commercial meat-type (MT) chickens, even in the presence of maternal antibodies. In this study, we evaluated the protection provided by a recombinant herpesvirus of turkeys (rHVT) vaccine delivered at either a standard dose (SD) or a high dose (HD) against splenocyte damage induced by the vv + MDV strain 686 in MT chickens. Results showed that both rHVT-SD and rHVT-HD protected against the 686-induced reduction in splenocyte lymphoproliferative responses to concanavalin A (ConA) ex vivo and modestly, albeit not significantly, reduced 686 replication in the spleen at 6 days post-infection (dpi). However, by 25 dpi, neither vaccine dose limited the 686 DNA load in the spleen. Protection against splenic immunophenotypic alterations at 25 dpi was suboptimal; neither rHVT-SD nor rHVT-HD prevented the reduction in the number of live splenocytes, B cells, or KUL01+MHC-IIhigh+ APCs. However, modest improvements were observed; the rHVT-SD/686 group showed slightly higher percentages of live splenocytes and B cells than the 686-infected group, whereas the rHVT-HD/686 group exhibited a numerical increase only in B cells. Furthermore, rHVT vaccination influenced the percentage of activated T cells. Both rHVT-SD and rHVT-HD vaccinations decreased the percentage of activated CD4+ T cells. The percentage of activated CD8α+ T cells was also reduced in both vaccine groups, but the reduction was significant only in the HD group, whereas the proportion of activated CD8β+ T cells decreased only in the SD-vaccinated group. In addition, both vaccine doses reduced the percentage of γδ+ T cells. Overall, our findings demonstrate that vaccination with rHVT provided partial protection against vv + MDV 686-induced immunophenotypic changes in the spleen, with no added benefit from using a higher rHVT-vaccine dose.